Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets. - Wikidata - wikimedia - TriplyDB

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

http://www.wikidata.org/entity/Q45168636

about

Risperidone versus placebo for schizophrenia Investigating Cortical Inhibition in First-Degree Relatives and Probands in Schizophrenia Clinical utility of the risperidone formulations in the management of schizophrenia.Effectiveness of switching from long-acting injectable fluphenazine or haloperidol decanoate to long-acting injectable risperidone microspheres: an open-label, randomized controlled trial.Resource utilization in patients with schizophrenia who initiated risperidone long-acting therapy: results from the Schizophrenia Outcomes Utilization Relapse and Clinical Evaluation (SOURCE).The 2009 schizophrenia PORT psychopharmacological treatment recommendations and summary statements The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review.Long-Acting Injectable Paliperidone Palmitate: A Review of Efficacy and Safety.Effectiveness of injectable risperidone long-acting therapy for schizophrenia: data from the US, Spain, Australia, and Belgium.Assessment of effectiveness measures in patients with schizophrenia initiated on risperidone long-acting therapy: the SOURCE study results World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of schizophrenia, part 2: update 2012 on the long-term treatment of schizophrenia and management of antipsychotic-induced side effects.The role of long-acting injectable antipsychotics in schizophrenia: a critical appraisal.Almost all antipsychotics result in weight gain: a meta-analysis.Adverse effects associated with second-generation antipsychotic long-acting injection treatment: a comprehensive systematic review.Evidence for inhibitory deficits in the prefrontal cortex in schizophrenia.Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study Long-acting injectable risperidone in partially adherent and nonadherent patients with schizophrenia.Treatment-completion rates with olanzapine long-acting injection versus risperidone long-acting injection in a 12-month, open-label treatment of schizophrenia: indirect, exploratory comparisons.Paliperidone palmitate injection for the acute and maintenance treatment of schizophrenia in adults.Pharmacoeconomic analysis of paliperidone palmitate for treating schizophrenia in Greece.Association between non-compliance with psychiatric treatment and non-psychiatric service utilization and costs in patients with schizophrenia and related disorders.Hospitalization rates in patients switched from oral anti-psychotics to aripiprazole once-monthly: final efficacy analysis Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France.Improving social cognition in schizophrenia: a pilot intervention combining computerized social cognition training with cognitive remediation.Risperidone long-acting injection: safety and efficacy in elderly patients with schizophrenia.Long-acting injectable paliperidone palmitate versus oral paliperidone extended release: a comparative analysis from two placebo-controlled relapse prevention studies Impact of risperidone long acting injection on resource utilization in psychiatric secondary care.A review of the association between antipsychotic use and hyperprolactinaemia.Dropout rates in randomized clinical trials of antipsychotics: a meta-analysis comparing first- and second-generation drugs and an examination of the role of trial design features Progress in compliance research and intervention: a commentary.Use of long-acting risperidone in psychiatric disorders: focus on efficacy, safety and cost-effectiveness.Long-acting risperidone injection: efficacy, safety, and cost-effectiveness of the first long-acting atypical antipsychotic.Risperidone long-acting injection in the treatment of schizophrenia: 24-month results from the electronic Schizophrenia Treatment Adherence Registry in Canada.Impact of dose frequency on compliance and health outcomes: a literature review (1966-2006).Long-acting atypical injectable antipsychotics in the treatment of schizophrenia: safety and tolerability review.Explicit review of risperidone long-acting injection prescribing practice.Evaluating appropriateness of prescribing of long-acting risperidone for injection in acute care settings.Oral versus Long-Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Special Populations at Risk for Treatment Nonadherence: A Systematic Review.Long-acting injectable formulations of new-generation antipsychotics: a review from a clinical perspective.New second-generation long-acting injectable antipsychotics for the treatment of schizophrenia.

P2860

Q24241041-6C595C99-5CAD-415A-822E-E0AC1F1DA7BF Q30358965-E748CAB6-C052-45DA-9D8F-F381F3B792F8 Q30429721-42CE5689-D948-4FFB-B4FB-7DFE02EDDDD5 Q30542486-127F521A-473B-40F6-B04D-BE0567A4B3DD Q31038656-7A3FB233-692C-473B-9473-54ABB50470F8 Q33566124-48ACB4C6-BBFF-42EE-AD87-7B401ABF8390 Q33619940-0E29DC9C-F7DF-4008-B8F5-C2A0FC0282A7 Q33802918-F6307EAC-59F4-482A-A841-AC5914912CAA Q33862078-16310B99-3AB2-4A4A-848A-8E6875BB4FD1 Q34048194-9EAF77B0-1E1B-4125-A038-44E28997BE14 Q34315836-EFCA10F6-3C8E-458A-83F8-EB46D2138B2A Q34418847-31D80086-9091-453D-B1FD-ED2E3E20B653 Q34661499-9B6052CB-E172-4EB4-8EF1-EAB9C207F962 Q34775426-5F684FDF-9734-42B7-B1AC-1A664DD35C30 Q35014889-309EA125-B83B-4A2A-8573-62AFE4D6F193 Q35030003-E85FBC1F-2543-404B-B765-7494853F9795 Q35143555-AB805CDC-FC01-42FF-AFDB-DEC2E7A5F6EA Q35971060-2D17662E-3B72-4AD7-9498-8268B680D1F1 Q36144552-00C49741-B01E-47A9-BB49-0DB2294AC169 Q36198389-E20350FA-6419-4AAC-ABD3-1BD8B8F06CF1 Q36220825-DD8F7557-FCBE-4DE7-AEFF-6A14521A348F Q36550998-46C6C627-041B-4AEE-A1EB-4101D040B3B3 Q36698856-C9343C1B-A666-400E-90BF-C41F8CB96747 Q36770010-436DD729-4153-49F1-9B08-FA379D68EB04 Q36873892-B3BF83F9-295F-4CF8-AA60-35BC51E40A88 Q37042180-0077FA03-4853-44D3-BB0D-05AC145236D1 Q37097631-5AEDF526-AB57-443F-AC85-A55695CE29FC Q37162798-08259AA2-AC60-4934-B0F5-41E8E42A8849 Q37227479-6B2760F2-FAD0-458E-931B-4E2BE65C2153 Q37236153-E8FC76BE-0EEB-4B42-B0B8-AFA5ACDE0BD1 Q37356486-6C61E98E-CA50-44A0-9095-C22FC31073FB Q37418931-CE2E37C2-70AF-40C7-96E4-7F08F0C53DFC Q37616971-BC32D2E7-3D0C-4AC9-B8BB-C8F2CAAA8E49 Q37763151-AB3CA444-2D0C-4D10-A455-0E7C034D4E5F Q37778398-6B6E91FF-176C-4519-95C4-E035534BEE05 Q37948911-6428B231-E9DD-4A0E-9D0F-D7E8376A3EF6 Q38000246-A0AC1302-37D7-42B7-9C61-05682EBFB269 Q38042430-2F18569B-009A-4538-8DB7-BC58A3265ED7 Q38115487-B2C4C23C-3878-4365-8E60-218B4359052A Q38125213-FE220078-2B36-4A6A-B83D-0F927F9B9D8B

P2860

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

http://www.wikidata.org/entity/Q45168636

description

2005 nî lūn-bûn

@nan

2005年の論文

@ja

2005年学术文章

@wuu

2005年学术文章

@zh

2005年学术文章

@zh-cn

2005年学术文章

@zh-hans

2005年学术文章

@zh-my

2005年学术文章

@zh-sg

2005年學術文章

@yue

2005年學術文章

@zh-hant

name

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@en

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@nl

type

label

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@en

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@nl

prefLabel

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@en

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@nl

P1433

Q45168636-86A6D630-554B-4B15-8514-E56A4468DC11

P1476

Q45168636-79518FD7-674F-45C1-B84D-5E45DDD4CD13

P2093

Q45168636-102B0062-6F49-4931-B7B6-BA9B4C4B0CCC

Q45168636-1A6B259A-85D7-474D-89B9-7F48B34867F4

Q45168636-6A206EC6-6937-4FBE-87F4-37E3D7DCAD00

Q45168636-8AED84CA-1FC4-4F24-A5AB-28A28127E1D6

Q45168636-B030A8CC-E618-4DEA-AF89-801B4E071F59

Q45168636-B2F4C29E-A1DB-4C93-B9C1-0D34F46C16B3

Q45168636-C204C710-7B21-419E-A3B7-BDD34066D16F

Q45168636-C4DBE561-AD79-481B-B71C-6673C503EB41

P304

Q45168636-410EF2CB-F5AB-4BEC-A29A-681786A4B7DD

P31

Q45168636-1BB6B3F8-E514-43D6-AFEA-9516B1CDC94B

P356

Q45168636-C569720E-2055-4476-8AC0-EEAE00BEFA25

P407

Q45168636-0F42A388-D449-498E-A344-434FEF21B3E7

P433

Q45168636-742248CC-53D5-4471-A030-38024C85B8BC

P478

Q45168636-E2B121AE-638A-4A75-A035-0A1C57A02D36

P577

Q45168636-E9FCF810-AAC4-4AD3-9442-46245B12D275

P698

Q45168636-34017A33-B8B5-4377-BA9E-B7DE75BB0942

P356

J.EURONEURO.2004.07.003

P1433

European Neuropsychopharmacology

P1476

Comparative efficacy and safety of long-acting risperidone and risperidone oral tablets.

@en

P2093

Anthony S David

http://www.w3.org/2001/XMLSchema#string

Bernard Lachaux

http://www.w3.org/2001/XMLSchema#string

H Pretorius

http://www.w3.org/2001/XMLSchema#string

Ilse Augustyns

http://www.w3.org/2001/XMLSchema#string

Lars Eriksson

http://www.w3.org/2001/XMLSchema#string

Marielle Eerdekens

http://www.w3.org/2001/XMLSchema#string

Peter Molcan

http://www.w3.org/2001/XMLSchema#string

Pierre Chue

http://www.w3.org/2001/XMLSchema#string

P304

111-117

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1016/J.EURONEURO.2004.07.003

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

15

http://www.w3.org/2001/XMLSchema#string

P577

2005-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

15572280

http://www.w3.org/2001/XMLSchema#string